- Case report
- Open Access
Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel's diverticulum; an unusual association
© Kosmidis et al; licensee BioMed Central Ltd. 2009
- Received: 01 January 2009
- Accepted: 23 March 2009
- Published: 23 March 2009
Coexistence of gastrointestinal stromal tumor with synchronous or metachronous colorectal cancer represents a phenomenon with increasing number of relative reports in the last 5 years. Synchronous occurence of GISTs with other gastrointestinal tumors of different histogenesis presents a special interest. We herein report a case of GIST in Meckel's diverticulum synchronous with colorectal adenocarcinoma.
A 69 year old man, presented with abdominal distension and anal bleeding on defecation. Colonoscopy revealed colorectal cancer and a low anterior resection was performed, during which a tumor in Meckel's diverticulum was discovered. Histologic examination revealed GIST in Meckel's diverticulum and a rectosigmoid adenocarcinoma.
Whenever GIST is encountered, the surgeon should be alert to recognize a possible coexistent tumor with different histological origin. Correct diagnosis of synchronous tumors of different origin is the cornerstone of treatment.
- Gastrointestinal Stromal Tumor
- Colorectal Adenocarcinoma
- Mitotic Count
- Smooth Muscle Tumor
Meckel's diverticulum is surgically removed only when a complication arises or a neoplasia develops. Neoplastic transformation has been reported, but gastrointestinal stromal tumors (GISTs) are exceptional in this location [1, 2]. The management of GISTs has dramatically evolved over the last ten years. However, their coexistence with other gastrointestinal tumors of different histogenesis presents a special clinical problem. We herein report a case of GIST in Meckel's diverticulum synchronous with colorectal adenocarcinoma.
A 69 year-old-man presented with abdominal distension and anal bleeding on defecation. For the last six months the patient was complaining of flatulence, periumbilical pain and sensation of incomplete evacuation. Apart from tenderness on deep palpation, blood on PR examination and increased bowel sounds, all other systems were found normal on clinical examination.
Patient's postoperative course was uneventful, and he was commenced on adjuvant chemotherapy with FOLFOX regimen (oxaliplatin i.v., 85 mg/m2(on day 1), leukovorin i.v., 200 mg/m2 (on days 1,2), 5 FU (fluorouracil) i.v., bolus 400 mg/m2 (on days 1,2), 5 FU i.v., 22 hours-infusion, 600 mg/m2 (on days 1,2), every 2 weeks for 12 cycles.
One year later he has no signs of local recurrence or metastasis.
The term GIST was introduced by Mazur and Clark in 1983 in order to define a heterogeneous group of neoplasms of spindle and epithelioid cells arising from the stroma with no definite cell line of origin and varying patterns of differentiation [4, 5]. GISTs are considered to be mesenchymal neoplasms, encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors, which, with the implementation of immunohistochemical stains and electron microscopy in recent years, have been recognized as a distinct pathological entity . Their nomenclature, histogenesis, criteria for diagnosis, prognostic manifestations, and classification have raised much debate and controversy [6, 7]. Though the most common mesenchymal tumors in the gastrointestinal tract wall, arising from Cajal's cells, they are rare neoplasms accounting for less than 1% of all gastrointestinal tumors .
The most common sites are stomach (60%) and small intestine (30%). The average presentation is in the sixth decade . Most GISTs (>90%) express CD117, the c-kit proto-oncogene protein that is a transmembrane receptor for the stem cell growth factor, and 70% to 80% express CD34, the human progenitor cell antigen; less often, these tumors stain positive for actin and desmin .
The three most important factors in determining malignancy are mitotic rate, tumor size and site [8, 10–12]. Mitotic counts higher than 2 per 50 high-power fields imply an increased risk for local recurrence in small bowel GIST . It is generally accepted that the criteria for predicting biological behavior may differ significantly with location. For example gastric GISTs are less aggressive than those located in small bowel. In the small intestine there is an overall 39% tumor related mortality, twice that for gastric GISTs [8, 13].
Smaller GISTs are often incidental findings during surgery, radiologic studies, or endoscopy. Coexisting stromal tumors are usually very small and are detected incidentally during gastrointestinal surgery for carcinomas . In our case the patient presented with anal bleeding, which was attributed to the colorectal carcinoma. Preoperative evaluation did not reveal the unique coexistence of tumor in Meckel's diverticulum along with the rectosigmoid cancer, even though the tumor was large, 7.5 cm in maximal diameter.
The patient underwent an en-block resection of the tumor to avoid rupture and intra-abdominal spillage, as it is recommended . He was commenced on adjuvant chemotherapy with oxaliplatin, leukovorin, and fluorouracil. Imatinib mesylate was not used since treatment of localized GIST is complete surgical excision, without dissection of lymph nodes [11, 12] and adjuvant treatment with imatinib is still under consideration. Imatinib is the standard treatment if complete surgery is not feasible . As the localized GIST was excised intact, there was no rationale to submit the patient to a treatment that should be continued indefinitely and the long-term success of which is limited by development of imatinib resistance via secondary mutations or clonal selection .
Despite the considerable development in the management of GISTs the last 10 years and the immense progress recently made in understanding the molecular biology of GISTs, little is yet known about their rare synchronous occurrence with tumors of different histogenesis. GISTs have been reported to occur synchronously with colon adenocarcinoma, gastric cancer, lymphoma and carcinoid [13, 15–18]. The coexistence of GIST with either synchronous or metachronous colorectal cancer represents a rare phenomenon with increasing number of relative reports in the last 5 years.
Although the synchronous occurrence of GIST and other abdominal malignancy seems to be just a coincidence, combined genetic deregulation or influenced neighboring tissues by the same carcinogen could be causative factors [17, 19]. There are some data regarding the co-occurrence, the association and the potential common origin (genetic pathways of tumorigenesis), between GIST and other tumors [18–20]. The limited number of these cases cannot confirm the existence of a common factor in tumorigenesis of these histopathologically completely different tumors and further studies are needed to clarify the possible association.
Most of the published cases describe gastric stromal tumors synchronous with another gastric malignancy. Our case describes a concomitant GIST in Meckel's diverticulum with a colorectal adenocarcinoma. As far as we could elicit from the literature, this is the first report of such tumor coexistence with regard to location.
The role of thorough abdominal exploration despite advanced preoperative imaging techniques cannot be overemphasized. In case of colorectal cancer, the doctor should bear in mind the possibility of coexistent tumor with different histological origin elsewhere in the GI tract.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Haber JJ: Meckel's diverticulum. Am J Surg. 1947, 73: 468-485. 10.1016/0002-9610(47)90329-2.View ArticlePubMedGoogle Scholar
- Chandramohan K, Agarwal M, Gurjar G, Gatti RC, Patel MH, Trivedi P, Kothari KCL: Gastrointestinal stromal tumour in Meckel's diverticulum. WJSO. 2007, 5: 50-10.1186/1477-7819-5-50.Google Scholar
- Fletcher CD, Berman J, Corless CL, Gorstein F, Lasota J, Longley B, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.View ArticlePubMedGoogle Scholar
- Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983, 7: 507-519.View ArticlePubMedGoogle Scholar
- Feldeman M, Scharschmidt BF, Sleisenger MH: Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 1998, Philadelphia: W.B. Saunders, 6Google Scholar
- Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S: Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002, 33: 669-676. 10.1053/hupa.2002.124116.View ArticlePubMedGoogle Scholar
- Yamada T: Textbook of Gastroenterology. 2003, Philadelphia: Lippincott Williams & Wilkins, 4Google Scholar
- Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478.PubMedGoogle Scholar
- De Matteo RP: The GIST of targeted cancer therapy: A tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002, 9: 831-839. 10.1007/BF02557518.View ArticleGoogle Scholar
- D'Amato G, Steinert DM, McAuliffe JC, Trent JC: Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005, 12: 44-56.PubMedGoogle Scholar
- Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, ESMO Guidelines Working Group: Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow up. Annals of Onc. 2008, 19 (S2): ii35-38. 10.1093/annonc/mdn080.Google Scholar
- Weber AG, Jovenin N, Lubrano D, Journu J, Yaziji N, Bouche O, Diebold MD, Delattre JF: Outcome after surgical treatment of gastrointestinal stromal tumors. Gastroenterol Clin Biol. 2007, 31: 579-584.View ArticlePubMedGoogle Scholar
- Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, Krasnodebski IW: Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol. 2006, 12: 5360-5362.PubMed CentralPubMedGoogle Scholar
- Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M: Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006, 23: 120-129. 10.1053/j.semdp.2006.09.004.View ArticlePubMedGoogle Scholar
- Kaffes A, Hughes L, Hollinshead J, Katelaris P: Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach. J Gastroenterol Hepatol. 2002, 17: 1033-1036. 10.1046/j.1440-1746.2002.02649.x.View ArticlePubMedGoogle Scholar
- Kover E, Faluhelyi Z, Bogner B, Kalmar K, Horvath G, Tornoczky T: Dual tumors in the GI tract: synchronous and metachronous stromal (GIST) and epithelial/neuroendocrine neoplasms. Magy Onkol. 2004, 48: 315-321.PubMedGoogle Scholar
- Maiorana A, Fante R, Cesinaro MA, Fano AR: Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med. 2000, 124: 682-686.PubMedGoogle Scholar
- Usui M, Matsuda S, Suzuki H, Hirata K, Ogura Y, Shiraishi T: Somatostatinoma of the papilla of Vater with multiple gastrointestinal stromal tumors in a patient with von Recklinghausen's disease. J Gastroenterol. 2002, 37: 947-953. 10.1007/s005350200159.View ArticlePubMedGoogle Scholar
- Andea AA, Lucas C, Cheng JD, Adsay NV: Synchronous occurrence of epithelial and stromal tumors in the stomach. Arch Pathol Lab Med. 2001, 125: 318-319.PubMedGoogle Scholar
- Sugimura T, Fujimura S, Baba T: Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1970, 30: 455-465.PubMedGoogle Scholar
- Miettinen M, Makhlouf HR, Sobin LH, Lasota J: Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol. 2006, 30: 477-489. 10.1097/00000478-200604000-00008.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.